Scott M. Coiante
2023
In 2023, Scott M. Coiante earned a total compensation of $400K as Former Chief Financial Officer at Aprea Therapeutics, a 61% decrease compared to previous year.
Compensation breakdown
| Salary | $100,000 |
|---|---|
| Other | $300,000 |
| Total | $400,000 |
Coiante received $300K in other compensation, accounting for 75% of the total pay in 2023.
Coiante also received $100K in salary.
Rankings
In 2023, Scott M. Coiante's compensation ranked 2,282nd out of 3,006 executives tracked by ExecPay. In other words, Coiante earned more than 24.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,282 out of 3,006 | 24th |
Division Manufacturing | 1,288 out of 1,650 | 22nd |
Major group Chemicals And Allied Products | 768 out of 918 | 16th |
Industry group Drugs | 750 out of 881 | 15th |
Industry Pharmaceutical Preparations | 540 out of 637 | 15th |
Source: SEC filing on April 25, 2024.
Coiante's colleagues
We found two more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2023.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020